Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for COVID-19 Treatment
NCT04445311Phase 3Unknown
- Sponsor
- Zagazig University
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Zagazig University. Primary endpoint: Time to be symptoms free at 21 days. Status: unknown.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04445311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445311.